Assessing the available techniques for testing myocardial viability: what does the future hold?

Area of Science:

• Cardiology
• Medical Imaging
• Cardiovascular Disease

Background:

• Severe coronary artery disease (CAD) with left ventricular dysfunction presents a complex clinical challenge.
• Patients with CAD and reduced ejection fraction have poor prognoses, but outcomes vary after revascularization.
• Irreversibly scarred myocardium may not benefit from revascularization, unlike viable but hibernating myocardium.

Purpose of the Study:

• To review the role and current evidence regarding myocardial viability testing in patients with ischemic cardiomyopathy.
• To discuss the potential benefits and limitations of viability assessment in guiding therapeutic strategies.
• To highlight emerging technologies in the field of viability testing.

Main Methods:

• Review of existing literature on myocardial viability testing in ischemic cardiomyopathy.
• Discussion of various noninvasive imaging modalities for assessing myocardial viability.
• Consideration of the predictive value of viability testing for functional recovery and prognosis.

Main Results:

• Myocardial viability testing can predict regional and global functional recovery of the left ventricle.
• The ability of current viability studies to predict long-term survival and overall prognosis is not yet definitively proven in prospective studies.
• Some patients with hibernating myocardium may benefit from revascularization, while those with transmural infarction are less likely to recover function.

Conclusions:

• Myocardial viability testing is a valuable tool for selecting patients who may benefit from revascularization, despite inconclusive data on survival benefits.
• Noninvasive viability assessment aids in tailoring treatment strategies for patients with ischemic cardiomyopathy.
• Advancements in imaging technologies like PET and cardiac MRI are expected to further refine viability assessment in the future.